Verso una nuova fonte di β-cellule per la cura del diabete mellito di tipo 1

Il Diabete Pub Date : 2022-07-11 DOI:10.30682/ildia2202h
V. Zamarian, Silvia Pellegrini, Valeria Sordi
{"title":"Verso una nuova fonte di β-cellule per la cura del\ndiabete mellito di tipo 1","authors":"V. Zamarian, Silvia Pellegrini, Valeria Sordi","doi":"10.30682/ildia2202h","DOIUrl":null,"url":null,"abstract":"Pluripotent stem cells are the best candidates for a renewable and infinite source of β-cells suitable for a future application in cell ther-apy for type 1 diabetes. Obtaining a cellular product that is safe and functional is becoming urgent, as the first clinical trials using stem cell-derived β cells are ongoing. This review summarizes the current strategies applied in the field of stem cell derived-β cells to improve in vitro differentiation and to solve the problems of tumorigenicity and immune rejection for a future stem cell based cell therapy.","PeriodicalId":119243,"journal":{"name":"Il Diabete","volume":"23 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Il Diabete","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30682/ildia2202h","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Pluripotent stem cells are the best candidates for a renewable and infinite source of β-cells suitable for a future application in cell ther-apy for type 1 diabetes. Obtaining a cellular product that is safe and functional is becoming urgent, as the first clinical trials using stem cell-derived β cells are ongoing. This review summarizes the current strategies applied in the field of stem cell derived-β cells to improve in vitro differentiation and to solve the problems of tumorigenicity and immune rejection for a future stem cell based cell therapy.
迈向新的β来源照顾deldiabete -cellule 1型糖尿病;
多能干细胞是一种可再生和无限来源的β细胞的最佳候选者,适用于未来1型糖尿病的细胞治疗。由于使用干细胞来源的β细胞的首批临床试验正在进行中,获得一种安全和功能性的细胞产品变得越来越紧迫。本文综述了目前干细胞源性β细胞在体外分化、解决致瘤性和免疫排斥问题方面的研究进展,为未来干细胞治疗提供参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信